110 related articles for article (PubMed ID: 3260852)
1. In vitro activity of cefotaxime against clinically significant pathogens.
Nakashio S; Nakamura M
Drugs; 1988; 35 Suppl 2():14-21. PubMed ID: 3260852
[TBL] [Abstract][Full Text] [Related]
2. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.
Hall WH; Opfer BJ; Gerding DN
Antimicrob Agents Chemother; 1980 Feb; 17(2):273-9. PubMed ID: 6247970
[TBL] [Abstract][Full Text] [Related]
3. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime].
Le Noc P; Bryskier A; Le Noc D
Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972
[TBL] [Abstract][Full Text] [Related]
4. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains].
Mascellino MT; Prignano G; Iegri F; Lorenzi A
Boll Ist Sieroter Milan; 1982; 61(4):309-19. PubMed ID: 6100234
[TBL] [Abstract][Full Text] [Related]
5. Ceftizoxime (FK 749) in vitro antibacterial activity.
Husson MO; Courcol R; Izard D; Leclerc H
Infection; 1984; 12(1):40-5. PubMed ID: 6323320
[TBL] [Abstract][Full Text] [Related]
6. Ceftriaxone: a summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-micrograms disks.
Jones RN; Barry AL; Thornsberry C
Diagn Microbiol Infect Dis; 1983 Dec; 1(4):295-311. PubMed ID: 6321093
[TBL] [Abstract][Full Text] [Related]
7. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.
Jones RN; Thornsberry C
Rev Infect Dis; 1982; 4 Suppl():S300-15. PubMed ID: 6294779
[TBL] [Abstract][Full Text] [Related]
8. [Antibiotic activities of cefuzoname and the representative cephalosporins against clinically isolated methicillin resistant strains of Staphylococcus].
Arai T
Jpn J Antibiot; 1986 May; 39(5):1237-40. PubMed ID: 3463774
[TBL] [Abstract][Full Text] [Related]
9. In-vitro evaluation of Sch 34343: antimicrobial activity, beta-lactamase stability and inhibition.
Jones RN; Barry AL; Fuchs PC; Thornsberry C
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():99-109. PubMed ID: 3875606
[TBL] [Abstract][Full Text] [Related]
10. [Sensitivity to cefotiam of 494 hospital bacterial strains. Determination of minimal inhibitory concentration and comparison with other beta-lactams].
Reynaud A; Desnoes M; Derriennic M; Courtieu AL
Pathol Biol (Paris); 1985 May; 33(5):313-9. PubMed ID: 3929216
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of cefmenoxime (SCE-1365).
Stamm JM; Girolami RL; Shipkowitz NL; Bower RR
Antimicrob Agents Chemother; 1981 Mar; 19(3):454-60. PubMed ID: 6264846
[TBL] [Abstract][Full Text] [Related]
12. Cefoxitin sensitivity as a marker for inducible beta-lactamases.
Moritz VA; Carson PB
J Med Microbiol; 1986 May; 21(3):203-7. PubMed ID: 3486293
[TBL] [Abstract][Full Text] [Related]
13. Synergistic enhancement of in vitro antimicrobial activity of imipenem and cefazolin, cephalothin, cefotiam, cefamandole or cefoperazone in combination against methicillin-sensitive and -resistant Staphylococcus aureus.
Uete T; Matsuo K
Jpn J Antibiot; 1995 Mar; 48(3):402-8. PubMed ID: 7752453
[TBL] [Abstract][Full Text] [Related]
14. The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides.
Seibert G; Limbert M; Winkler I; Dick T
Infection; 1983; 11(5):275-9. PubMed ID: 6315595
[TBL] [Abstract][Full Text] [Related]
15. Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria.
Fuchs PC; Jones RN; Thornsberry C; Barry AL; Gerlach EH; Sommers HM
Antimicrob Agents Chemother; 1981 Dec; 20(6):747-59. PubMed ID: 6275784
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activities of third-generation cephalosporins.
Fass RJ
Arch Intern Med; 1983 Sep; 143(9):1743-5. PubMed ID: 6615095
[TBL] [Abstract][Full Text] [Related]
17. [The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics].
Miwatani T; Takeda Y; Kotera K; Nishimura T; Takashima T; Hiromatsu K; Tabuki K; Fujimoto S; Kamiki T; Yoshizaki E; Yabuuchi E; Shimizu Y; Matsunaga K; Yamanaka K; Furuta I; Iimori M; Kodama J; Tanaka M; Maejima K; Nukina M; Takashima E; Takahashi M; Harikane O; Masutani T
Jpn J Antibiot; 1983 Feb; 36(2):260-76. PubMed ID: 6304368
[TBL] [Abstract][Full Text] [Related]
18. In-vitro antibacterial activity of L-105, a new cephalosporin.
Hikida M; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1986 Nov; 18(5):585-91. PubMed ID: 3492485
[TBL] [Abstract][Full Text] [Related]
19. Comparative in vitro antibacterial activity of aztreonam against clinical isolates of gram-negative bacteria.
Shibl AM; Ishag AH; Durgham SM
Chemotherapy; 1989; 35 Suppl 1():72-6. PubMed ID: 2659292
[TBL] [Abstract][Full Text] [Related]
20. [beta-lactamase-producing activity and antimicrobial susceptibility of major pathogenic bacteria isolated from clinical samples. Japan beta-lactamase Research Group].
Oguri T; Igari J; Hiramatsu K; Watanabe A; Inoue M; Abe M; Yamane N; Aihara M; Hashimoto H;
Jpn J Antibiot; 2002 Sep; 55 Suppl A():1-28. PubMed ID: 12599526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
